Home Featured Page 275

Featured

Latest

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding

From Individualism to Connection: How Psychedelics and Group Therapy Can Heal Our Collective Crisis

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

1...273 274275Page 275 of 275

EDITOR PICKS

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding

From Individualism to Connection: How Psychedelics and Group Therapy Can Heal Our Collective Crisis

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

EDITOR PICKS

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY